Category: St. Jude MedicalSyndicate content

In defense of renal denervation: Managing expectations in the aftermath of Symplicity HTN-3

January 20, 2014 by Arezu Sarvestani

Cardiologist Dr. Darrel Francis finds himself attempting once again to drag the conversation back from the edge of hyperbole as the market reacts to the lackluster outcome of Medtronic's highly anticipated Symplicity HTN-3 trial of renal denervation in treatment of hypertension.

Managing renal denervation expectations in the aftermath of Symplicity HTN-3

St. Jude Medical quietly lands FDA approval for Cool Flex cardiac ablation

January 17, 2014 by Arezu Sarvestani

St. Jude Medical quietly accepts FDA premarket approval for its Cool Flex ablation catheter and ablation generator for treatment of arrhythmia.

St. Jude Medical quietly lands FDA approval for Cool Flex cardiac ablation

Medtech titan St. Jude Medical (NYSE:STJ) won FDA premarket approval for its Cool Flex cardiac ablation system with indication to treat irregular heart rhythms.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Renal denervation 'highly unlikely' for hypertension, says Medtronic study insider

January 16, 2014 by Arezu Sarvestani

Medtronic's clinical trial flop may signal the end for renal denervation in treating hypertension, according to a co-principal investigator in Medtronic's SYMPLICITY HTN-3 trial.

Renal denervation is 'highly unlikely,' says Medtronic study insider

The future of renal denervation in treatment of hypertension is shaky at best, according to 1 of the principal investigators involved with Medtronic's disappointing clinical trial.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

J.P. Morgan medtech wrap-up: Ups and downs from San Francisco

January 16, 2014 by MassDevice staff

In case you couldn't make it to sunny San Francisco, here are some of the best medical device stories that came out of the J.P. Morgan Healthcare conference this week.

J.P. Morgan medtech wrap-up: Ups and downs from San Francisco

Medtronic CEO: Value-based healthcare is the only way to save medtech

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Boston Scientific stands fast on renal denervation

January 14, 2014 by Brad Perriello

Boston Scientific CEO Mike Mahoney says the company is still bullish on the prospects for its Vessix renal denervation platform for treating high blood pressure, despite the efficacy failure of Medtronic's gold-standard Symplicity HTN-3 trial.

Boston Scientific stands fast on renal denervation

St. Jude CEO: Medtronic's renal denervation miss doesn't dampen our spirits

January 13, 2014 by Arezu Sarvestani

St. Jude Medical president & CEO Dan Starks says that rival Medtronic's failed renal denervation study is no reason to stop pursuing the technology in treatment of hypertension.

St. Jude CEO: Medtronic's miss doesn't dampen our spirits

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

St. Jude Medical beats guidance with Q4 prelims

January 13, 2014 by Brad Perriello

St. Jude Medical says its preliminary results for the 4th quarter beat the high end of its prior forecast.

St. Jude Medical beats guidance with Q4 prelims

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp